Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis
Jingyang Su1,2, Cui Ni1, Yuqian Wu3
1Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Objectives:
To provide a more comprehensive understanding of the efficacy and safety profile of cabozantinib versus placebo in malignant tumors, we conducted a systematic review and meta-analysis. This involved analyzing a collection of published randomized controlled trials to assess the outcomes.
Methods:
We used RevMan5.3 software to evaluate the outcomes of the collected studies. The primary outcome we focused on was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and disease control rate (DCR).
Results:
Our findings revealed that compared to placebo, cabozantinib significantly extended the PFS of patients [hazard ratios (HR) 0.37, 95% confidence intervals (CI): 0.32, 0.43, p < 0.00001]. Additionally, cabozantinib improved the OS of patients [HR 0.78, 95%CI: 0.68, 0.91, p = 0.002]. While it is important to note that cabozantinib was associated with a higher likelihood of causing digestive, cutaneous, and cardiovascular related adverse events [relative risk (RR) 4.40, 95% CI: 3.10, 6.25, p < 0.00001].
Conclusion:
Based on our analysis, cabozantinib significantly prolonged the PFS and OS of patients with malignant tumors (p < 0.01). We recommend the use of cabozantinib in treating advanced malignant tumors. However, it is important to continuously monitor and manage the drug-related adverse events.
Registration:
PROSPERO (No. CRD42023449261).
Insights
Cabozantinib significantly improves progression-free survival (PFS) and overall survival (OS) in malignant tumors compared to placebo. While effective, cabozantinib increases risks of digestive, cutaneous, and cardiovascular adverse events.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Malignant tumors represent a significant global health challenge.
- Understanding the efficacy and safety of targeted therapies like cabozantinib is crucial for treatment optimization.
Approach:
- Systematic review and meta-analysis of published randomized controlled trials.
- Utilized RevMan5.3 software for outcome evaluation.
- Focused on progression-free survival (PFS), overall survival (OS), and disease control rate (DCR).
Key Points:
- Cabozantinib significantly extended PFS (HR 0.37, 95% CI: 0.32, 0.43, p<0.00001).
- Cabozantinib improved OS (HR 0.78, 95% CI: 0.68, 0.91, p=0.002).
- Increased risk of digestive, cutaneous, and cardiovascular adverse events observed (RR 4.40, 95% CI: 3.10, 6.25, p<0.00001).
Conclusions:
- Cabozantinib demonstrates significant efficacy in prolonging PFS and OS in patients with malignant tumors.
- Recommended for advanced malignant tumor treatment, with careful monitoring for adverse events.
- Continuous management of drug-related adverse events is essential.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...